RebrAIn’s news

FrenchWeb Highlights RebrAIn’s €3.7 Million Seed Funding for Parkinson’s Disease Innovation

frenchweb-highlights-rebrains-e3-7-million-seed-funding-for-parkinsons-disease-innovation

We are thrilled to share that FrenchWeb has featured RebrAIn for securing €3.7 million in seed funding to advance our AI-driven solutions for treating Parkinson’s Disease.

Led by Karista and supported by Nouvelle Aquitaine Co-Investissement, this funding will accelerate the international expansion of our innovative platform, OptimDBS, which aims to simplify and standardize Deep Brain Stimulation procedures. This significant investment underscores our commitment to enhancing patient outcomes and making neurosurgical treatments more accessible.

Read the full story here (in French).

An English translation by Google is available here.

Back to Resources

Our latest public updates

RebrAIn Hosts Inaugural Medical Advisory Board Meeting (MAB)

Oct 1, 2024

RebrAIn recently held the inaugural meeting of its Medical Advisory Board (MAB), marking a significant milestone in the company’s ongoing mission to deliver transformative AI-powered tools to neurosurgeons. The meeting also underscored RebrAIn's pivotal role in...

RebrAIn completes enrollment ahead of schedule for PARKEO2 clinical trial

Sep 30, 2024

RebrAIn is pleased to announce the early completion of enrollment for the second phase of the PARKEO2 clinical trial, a pioneering study aimed at improving surgical treatments for Parkinson’s disease. Sponsored by the Bordeaux University Hospital (CHU de Bordeaux) and...

RebrAIn Co-Founders to Present Innovative VIM Targeting Techniques at WSSFN Biennial Meeting

Sep 3, 2024

RebrAIn is excited to announce that its co-founders, Prof. Emmanuel Cuny, MD, and Prof. Nejib Zemzemi, PhD, will be presenting groundbreaking research on VIM targeting techniques at the upcoming World Society for Stereotactic and Functional Neurosurgery (WSSFN)...

« Older Entries

Next Entries »